Toward Distributed Robustness in Resistance-Aware Lead Optimization

Drug resistance often enters lead optimization after a compound has been chosen. We define distributed robustness as redistributing predicted binding support away from predefined mutable contacts while retaining wild-type feasibility and panel coverage. ResistAgent separates site-level and observed combination-level liabilities, diagnoses their structural effects, and compares a matched-budget robust objective with an average-affinity comparator. Across 10 EGFR pairs, the median reduction in hotspot dependence, ΔDep (naive − robust; positive values favor the robust objective), was +0.042; across 9 valid HIV-RT pairs, it was +0.026. Panel passing was preserved but not improved: both objectives passed in every valid pair. ABL1 yielded 2/4 pairs without a corresponding robustness gain. The objective changes the dependence organization and candidate selection. Provider comparisons, ranking benchmarks, and explicit-water contact descriptors are reported alongside the primary endpoint.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-18
DOI
https://doi.org/10.1021/acs.jmedchem.6c02107
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Toward Distributed Robustness in Resistance-Aware Lead Optimization

Yu Fu, Weiwei Han, Silvio E. Perea, Huizi Cui et al.
1 links
Journal of Medicinal Chemistry
Computational Drug Discovery Methods
article

Toward Distributed Robustness in Resistance-Aware Lead Optimization

Yu Fu, Weiwei Han, Silvio E. Perea, Huizi Cui, B Y Xiao, Yuxuan Wang, Wen Li, Jingyi Kang
article en

Abstract

Drug resistance often enters lead optimization after a compound has been chosen. We define distributed robustness as redistributing predicted binding support away from predefined mutable contacts while retaining wild-type feasibility and panel coverage. ResistAgent separates site-level and observed combination-level liabilities, diagnoses their structural effects, and compares a matched-budget robust objective with an average-affinity comparator. Across 10 EGFR pairs, the median reduction in hotspot dependence, ΔDep (naive − robust; positive values favor the robust objective), was +0.042; across 9 valid HIV-RT pairs, it was +0.026. Panel passing was preserved but not improved: both objectives passed in every valid pair. ABL1 yielded 2/4 pairs without a corresponding robustness gain. The objective changes the dependence organization and candidate selection. Provider comparisons, ranking benchmarks, and explicit-water contact descriptors are reported alongside the primary endpoint.

Journal of Medicinal Chemistry
Jilin University (CN), Hunan University of Science and Engineering (CN), Centro de Ingeniería Genética y Biotecnología (CU)
National Natural Science Foundation of China
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon